Primary Outcome Measures:
- Vaccine response to meningococcal antigens [ Time Frame: One month post vaccination ] [ Designated as safety issue: No ]
- Occurrence of any grade 3 systemic symptom [ Time Frame: During the 4-day follow-up period after vaccination ] [ Designated as safety issue: Yes ]
Secondary Outcome Measures:
- Meningococcal rSBA titres [ Time Frame: Prior to and one month after vaccination, in all subjects ] [ Designated as safety issue: No ]
- Anti-tetanus toxoid antibody concentration [ Time Frame: Prior to and one month after vaccination, in all subjects ] [ Designated as safety issue: No ]
- Anti-meningococcal polysaccharide concentrations [ Time Frame: Prior to and one month after vaccination, in a randomized subset of subjects ] [ Designated as safety issue: No ]
- Occurrence of solicited local and general symptoms [ Time Frame: During the 4-day follow-up period after vaccination ] [ Designated as safety issue: Yes ]
- Occurrence of unsolicited symptoms [ Time Frame: Up to one month after vaccination ] [ Designated as safety issue: Yes ]
- Occurrence of serious adverse events [ Time Frame: Up to six months after vaccination ] [ Designated as safety issue: Yes ]
- Occurrence of specific adverse events of rash, new onset of chronic illness(es) and conditions prompting emergency room visits and physician office visits not related to common illnesses [ Time Frame: Up to six months after vaccination ] [ Designated as safety issue: Yes ]
Multicentre study with 2 treatment groups. Each subject will have 2 blood samples taken for immunogenicity analyses, one prior to vaccination and one taken 30 days later.
The Protocol Posting has been updated in order to comply with the FDA Amendment Act, Sep 2007.